At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 22 enrolled
Drug / intervention
Quinine Sulfate 2 x 324 mg Capsules +1 moredrug
Likely dose
Quinine Sulfate 2 x 324 mg Capsulesfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg Under Fasting and Fed Conditions
In Brief
A Phase 1 clinical trial evaluating Quinine Sulfate 2 x 324 mg Capsules for Healthy. Completed, enrolled 22 participants.
Detailed Summary
The purpose of this study is to evaluate and compare the relative bioavailability of Quinine Sulfate capsules following a single, oral dose in healthy volunteers under fasting and fed conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
Primary CompletionDec 2005
First PostedAug 2008
TodayJul 2026
First PostedAug 1, 2008
Enrollment StartDec 1, 2005
Primary CompletionDec 1, 2005
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.9 years ago
Interventions
Quinine Sulfate 2 x 324 mg Capsulesdrug
Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
Quinine Sulfate 2 x 324 mg Capsulesdrug
Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.